ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 26, 2021 19:42 JST
Source:
Tianda Pharmaceuticals Limited
天大药业2021年中期业绩
业务显著增长
继续加强创新研发、加大业务拓展力度
香港, Nov 26, 2021 - (ACN Newswire) - 天大药业有限公司(天大药业或本集团 ,股份代号 :0455.HK) 欣然宣布截至2021年9月30日止六个月(报告期)的中期业绩。报告期内,本集团三个业务板块均录得显著增长,收入2亿3,650万港元,同比增长26.2%。本集团财务状况稳健,于2021年9月30日,净资产7亿7,700万港元,银行结余及现金2亿220万港元,加上未动用银行贷款额度7,780万港元,本集团具充足财务资源支持业务稳步发展。
中医药业务收入5,800万港元,同比增长64.2%。顺应国家对中医药产业的政策支持,本集团经过逾五年的努力已形成中医药全产业链布局,涵盖中药材贸易、中药饮片生产、中医药研发、中药全产品线及国内外购销。药物和医疗科技业务收入1亿7,490万港元,同比增长16.6%。主要产品心脑血管用药托平®缬沙坦胶囊在全国同类产品中销量第一,正抓住在国家第三批集中带量采购第一顺位中目标机会,放量增长。位于珠海金湾的新研发及制药基地将于明年1月投产,锐意打造成为一个高标准、高质量、高效能的医药健康产业基地。医疗和保健服务收入360万港元,同比增长79.5%。报告期内,首次采用股权投资合作模式与著名中医专家共同投资开设天大馆, 该合作模式将成为快速拓展天大馆的重要手段。同时,本集团加快构建中医云端科技平台「云上天大馆」,提供在线智能诊症、大健康电商等服务,与天大馆实体馆互相助力,致力发展「天大馆」成为中医馆第一品牌。
本集团继续加强创新和研发,在经典名方开发、心脑血管用药、儿科用药、糖尿病用药等方面均有序推进。同时,加大业务拓展(BD)力度,与研发有机联动,通过外部引进、自主研发、合作研发等方式,提高管线内研发项目的质量和数量,进一步丰富产品线,并在全球范围内寻找前沿技术和产品机会,助力公司整体业务发展。
国家在「第十四个五年规划和2035年远景目标纲要」中提出推动中医药传承创新,坚持中西医并重和优势互补,大力发展中医药事业,为本集团业务发展提供良好的政策红利。本集团将贯彻实施「三个发展」的战略,深度布局三大业务板块,积极审视并购机会,加快业务增长和规模扩大步伐,致力发展成为立足中国,辐射全球的领先医药企业,为守护人类健康做出更大贡献。
有关天大药业有限公司
天大药业有限公司(香港联交所上市公司,股份代号0455)以发展中医药产业为基础,发展创新药物和医疗科技,发展优质医疗和保健服务,致力发展成为立足中国,辐射全球的领先医药企业。
新闻查询
天大药业有限公司
投资者关系部
电话:+852 2545 3313 电邮:
ir@tianda.com
Source: Tianda Pharmaceuticals Limited
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
More Latest Release >>
Related Release
Tianda Pharma Announces 2022/23 Interim Results
November 25 2022 23:54 JST
Tianda Pharmaceuticals Annual Results 2022
June 30 2022 11:40 JST
Tianda Pharma Interim Results 2021
November 26 2021 18:40 JST
The third TDMall in the world opened in Sydney, Australia
March 16 2021 19:52 JST
Acquiring Xiaoer Qingre Zhike granule, Tianda Pharmaceuticals continues to broaden its product mix and perfect its Chinese medicine whole industry chain layout
March 04 2021 19:43 JST
Tianda Pharmaceuticals acquired and established a long-term relationship of Cooperation with Yeung & Young Medicare and Qi's Living
October 06 2020 11:00 JST
HK Main-Board Listed Tianda Pharmaceuticals (00455.HK) Promising Outlook for Growth
July 10 2020 15:26 JST
More Press release >>